The use of real-world evidence is growing fast in clinical drug development. And with good reason. Real-world evidence (RWE) is essential to determine the benefit/risk balance of treatments in routine clinical practice across populations and geographic regions and so improve patient outcomes.

Questions our partners ask us frequently:

  • When does real-world evidence add value to a drug development programme?
  • What do you need to consider before going ahead with an RWE study?
  • When does a pragmatic trial have advantages over an observational study?

From methodology to operations and from the emerging field of pragmatic trials to established use in observational studies, Julius Clinical, the science CRO, can help you turn real-world data into real-world evidence.